| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $11.0M | -22.6% |
| SG&A Expense | $10.9M | -21.4% |
| Operating Income | -$50.6M | +22.2% |
| Income Tax | -$712K | +53.9% |
| Net Income | -$49.9M | +20.7% |
| EPS (Basic) | -$1.96 | +44.2% |
| EPS (Diluted) | -$1.96 | +44.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.2M | -75.0% |
| Current Assets | $4.3M | -68.3% |
| Total Assets | $24.2M | -61.2% |
| Current Liabilities | $6.2M | +7.5% |
| Total Liabilities | $7.2M | -7.2% |
| Stockholders' Equity | $16.9M | -68.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$19.4M | +13.1% |
| Financing Cash Flow | $9.8M | -45.3% |